Morgan Stanley Initiates Cidara Therapeutics (CDTX) With a Buy

​Cidara Therapeutics, Inc. (NASDAQ:CDTX) is one of the Hot Growth Stocks to Invest in Now. On October 16, Maxwell Skor from Morgan Stanley initiated coverage of Cidara Therapeutics, Inc. (NASDAQ:CDTX) with a Buy rating and a price target of $190. ​The analyst noted the company’s lead candidate, CD388, as one of the key reasons backing his bullish sentiment. He believes that CD388, which is an antiviral, is positioned as a major player in the influenza prophylaxis market. This is because it offers single-d ...